19/08/2026 Phase 3 INTerpath-001 trial shows individualized mRNA therapy + KEYTRUDA improves survival in resected melanoma Phase 3 INTerpath-001 trial shows individualized mRNA therapy + KEYTRUDA improves survival in resected melanoma (Ref) Merck and Moderna announced that the Phase 3 INTerpath-001 trial evaluating intismeran autogene (V940/mRNA-4157), an individualized mRNA-based neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab. anti-PD-1), achieved its prima